Abstract:Current therapies for pulmonary arterial hypertension (PAH) mainly focus on the abnormalities in the prostacyclin, nitric oxide and endothelin pathways. These drugs fail to markedly improve morbidity and mortality, and thereby identification of novel druggable targets is still critically needed for effective treatment of PAH in patients. Our previous studies have identified the prerequisite role of HIF-2α activation in mediating obliterative pulmonary vascular remodeling and development of severe PAH (Dai, Circulation 2016), suggesting that targeting HIF-2α represents a novel strategy for the treatment of severe PAH. Our recent data showed that endothelial HIF-2α and its downstream targets are activated in IPAH patients. Pharmacological inhibition of HIF-2α with a novel HIF-2α-selective inhibitor markedly reduced right ventricle systolic pressure (RVSP) and RV hypertrophy and prevented right heart failure as well as inhibited pulmonary vascular remodeling in mice with Tie2Cre-mediated deletion of Egln1, which is the first mouse model of severe PAH recapitulating many of the characteristic features of clinical PAH including vascular occlusion and plexiform-like lesions as well as right heart failure. This compound also inhibited RVSP and RV hypertrophy and thereby PAH in rats challenged with Sugen 5416/Hypoxia. Together, these studies for the first time demonstrate that targeting HIF-2α is a promising therapeutic strategy for effective treatment of PAH and thereby promoting survival. Support or Funding Information NIH grants R01HL123957, R01HL125350, R01HL133951, and P01HL077806 (Project 3) to Y.Y.Z, AHA postdoctoral fellowship grant 15POST25700124 to Z.D. Activation of endothelial HIF-2a and its downstream targets in IPAH patients. (A) QRT-PCR analysis demonstrating increased of HIF-2a and its target genes in the lung of IPAH patients compared to that of normal donor. (B) Immunofluorescent staining showing increase of endothelial HIF-2a expression in the luminal side of pulmonary arterial of IPAH. V, vessels. *, p<0.05. HIF-2a inhibitors suppressed HIF-2a activation. (A) Luciferase assay showing that HIF-2a antagonist-2 (H2A) and HIF-2a translation inhibitor compound 76 (C76) inhibited DMOG (1mM) induced HIF activation in HLMECs. (B) Luciferase assay demonstrating that both H2A and C76 suppressed PHD2 silencing induced HIF activation in HLMECs. (C) QRT-PCR analysis showed that C76 selectively inhibited HIF-2a targets CXCL12, PDGFB, GREM1 but not CXCR4. *, P<0.05. ***, ###, P<0.001. Pharmacological inhibition of HIF-2a in severe PAH mouse model. (A) Strategy of C76 treatment in Egln1Tie2 mice. (B) Dramatic decrease of RVSP in C76 treated Egln1Tie2 mice. (C) Marked inhibition of RV hypertrophy in C76 treated Egln1Tie2 mice. (D)Echocardiography showing normalization of PA function by C76 treatment. (E) (F) Echocardiography measurement demonstrating increase of PA AT and PA AT/ET ratio in C76 treated Egln1Tie2 mice. **P<0.01; ***P<0.001. Normalization of pulmonary vasculature pathology and molecules by HIF-2a inhibition. (A) Representative Russel Movat pentachrome staining showing reduction of neointima, decrease of wall thickness and adventitia by in C76 treated Egln1Tie2 mice. (B) (C) Anti-a-SMA staining demonstrating decrease of distal pulmonary arterial muscularization in C76 treated Egln1Tie2 mice. (D) QRT-PCR analysis demonstrating normalization of PH-causing genes by C76 treatment in Egln1Tie2 mice. HIF-2a inhibitor inhibited RV hypertrophy and prevented RV failure. (A) (B) Echocardiography showing decrease of RV wall thickness in C76 treated Egln1Tie2 mice. (C) (D) Representative WGA staining showing that C76 decreased cardiomyocyte hypertrophy in vivo. (E) Trichrome staining showing reduction of RV fibrosis by C76. (F) Echocardiography showing restoration of RV fraction area change in C76 treated Egln1Tie2 mice. (G) Reduced mortality by C76 treatment in Egln1Tie2 mice.

Selective Targeting HIF‐2α for Treatment of Pulmonary Arterial Hypertension

Therapeutic Targeting of Vascular Remodeling and Right Heart Failure in Pulmonary Arterial Hypertension with a HIF-2α Inhibitor.

Endothelial Progenitor Cells May Inhibit Apoptosis of Pulmonary Microvascular Endothelial Cells: New Insights into Cell Therapy for Pulmonary Arterial Hypertension

Hif2 Alpha is Required for the Development of Pulmonary Vascular Fibrosis Associated with Pulmonary Arterial Hypertension

Abstract 12497: Diminished Cavolin-1 Expression and Augmented Nitrative Stress Secondary to Prolyl-4 Hydroxylase 2 Deficiency Contribute to Obliterative Vascular Remodeling and Severe Pulmonary Arterial Hypertension

Prolyl-4 Hydroxylase 2 (PHD2) Deficiency in Endothelial Cells and Hematopoietic Cells Induces Obliterative Vascular Remodeling and Severe Pulmonary Arterial Hypertension in Mice and Humans Through Hypoxia-Inducible Factor-2α

Diminished Cavolin-1 Expression And Augmented Nitrative Stress Secondary To Prolyl-4 Hydroxylase 2 Deficiency Contribute To Obliterative Vascular Remodeling And Severe Pulmonary Arterial Hypertension

Egln1Tie2Cre Mice Exhibit Similar Therapeutic Responses to Sildenafil, Ambrisentan, and Treprostinil as Pulmonary Arterial Hypertension (PAH) Patients, Supporting Egln1Tie2Cre Mice as a Useful PAH Model

Inhibition of Hsp110-STAT3 Interaction in Endothelial Cells Alleviates Vascular Remodeling in Hypoxic Pulmonary Arterial Hypertension Model

Phd2 Deficiency Induces Obliterative Vascular Remodeling and Severe Pah Through Nitrative Stress and Caveolin-1 Downregulation

Abstract 9804: Overexpression of Pericyte Hif2a Exacerbates Hypoxia Induced Pulmonary Hypertension and Right Ventricular Hypertrophy

Novel Pyrazolo[3,4-b] Pyridine Derivative (HLQ2g) Attenuates Hypoxic Pulmonary Hypertension via Restoring cGKI Expression and BMP Signaling Pathway

The Unexpected Role of GCN2 Kinase Activation in Mediating Pulmonary Arterial Hypertension

Endothelial PHD2 Deficiency Induces Nitrative Stress Via Suppression of Caveolin-1 in Pulmonary Arterial Hypertension

Abstract 11565: Improvement in Cardiopulmonary Function in a Rat Model of Pulmonary Arterial Hypertension Observed With RKER-012, a Novel Activin Receptor Type II Ligand Trap, was Associated With Reduced Markers of Inflammation and Fibrosis in the Right Ventricle

Inhibition of Siah2 Ubiquitin Ligase Ameliorates Monocrotaline-Induced Pulmonary Arterial Remodeling Through Inactivation of YAP

Abstract 14496: HIF2a Activation Reduces Pulmonary Angiogenesis and Promotes Vascular Remodeling in Pulmonary Arterial Hypertension by Suppressing Wnt7a Production in Pulmonary Endothelial Cells

TPN171H alleviates pulmonary hypertension via inhibiting inflammation in hypoxia and monocrotaline-induced rats

Genetic Ablation of PDGF-Dependent Signaling Pathways Abolishes Vascular Remodeling and Experimental Pulmonary Hypertension

Endothelial and Smooth Muscle Cell Interaction Via FoxM1 Signaling Mediates Vascular Remodeling and Pulmonary Hypertension

Established pulmonary hypertension in rats was reversed by a combination of a HIF‐2α antagonist and a p53 agonist